<DOC>
	<DOCNO>NCT00681213</DOCNO>
	<brief_summary>Comparison outcomes/safety/and tolerability SRL/FK/Pred vs. FK/MMF/Pred vs. SRL/NeoralÂ®/Pred cadaveric non-HLA identical LRD kidney transplant .</brief_summary>
	<brief_title>Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil ( MMF ) Versus Neoral/Sirolimus Adult , Primary Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age &gt; 14 year Weight &gt; 40 kg Primary renal allograft : cadaveric mismatch live donor Negative standard cross match Tcells Women childbearing potential require negative qualitative serum pregnancy test agree use adequate method contraception throughout study period 3 month discontinuation study medication ( 3yrs , 3 mo . ) Signed date informed consent ( Parent legal guardian must provide write consent patient &lt; 18 year age ) Evidence systemic infection History malignancy within 10 year ( exception localize skin cancer ) Use investigational drug treatment 4 week prior enrol study 12month treatment phase Concurrent use astemizole , pimozide , cisapride , terfenadine , ketoconazole Known hypersensitivity sirolimus derivative Patients screening/baseline ( within 96 hour transplant ) total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>